Study Evaluating SKI-606 (Bosutinib) In Subjects With Breast Cancer

• Status: Completed
• Trial end date: 2009-02-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to determine if SKI-606 (Bosutinib) is effective in the treatment of advanced or metastatic breast cancer. Patients must have current Stage IIIB, IIIC or IV breast cancer and have progressed after 1 to 3 prior chemotherapy regimens.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer

Criteria

Inclusion Criteria:

• Stage IIIB, IIIC or IV breast cancer not curable with available therapy.

• Patients must have progressed after 1 but not more than 3 prior chemotherapy regimens.

• Life expectancy of at least 16 weeks.

• Ability to swallow whole capsules.

Exclusion Criteria:

• Use of or requirement for bisphosphonates within 8 weeks prior to screening.

• Any other cancer within 5 years of screening, except for basal cell carcinoma or cervical carcinoma in situ

• Uncontrolled cardiac disease including congestive heart failure, angina, heart attack, etc.

• Recent or ongoing significant gastrointestinal disorder